Literature DB >> 22694926

Does gender influence outcomes in critically ill patients?

Martin K Angele, Sebastian Pratschke, Irshad H Chaudry.   

Abstract

Investigators continue to debate whether gender plays any role in patient outcome following injury/critical illness. We submit that age and hormonal milieu at the time of injury, rather than gender, are the critical factors influencing patient outcome under those conditions.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22694926      PMCID: PMC3580646          DOI: 10.1186/CC11365

Source DB:  PubMed          Journal:  Crit Care        ISSN: 1364-8535            Impact factor:   9.097


Mahmood and colleagues [1] performed a retrospective analysis, published in this issue of Critical Care, of 261,255 adult patients admitted to intensive care units (ICUs). The results indicate that women younger than 50 years old had lower ICU mortality in comparison with age-matched men, whereas mortality rate was similar in older patients. Female mortality, compared with male mortality, was increased following coronary artery bypass graft (CABG) surgery but decreased with chronic obstructive pulmonary disease (COPD) exacerbation. Gender-specific mortality rates were not evident for patients with acute coronary syndrome, sepsis, or trauma. Numerous experimental studies report gender-specific immune and cardiovascular responses [2-4]. Male gender was associated with suppressed immune responses and impaired cardiovascular function as opposed to maintained responses in proestrus females in experimental models of trauma-hemorrhage or sepsis (cecal ligation and puncture). In diestrus mice, immunoprotection was not evident. Proestrus mice are characterized by elevated estrogen plasma levels in comparison with mice in other phases of the estrus cycle. Gender-specific immune responses were reversed in aged mice [2-4]. In contrast, the referenced study [1] did not demonstrate gender-specific outcome in septic and trauma patients in any age group. Similarly, other clinical studies failed to consistently reproduce experimental findings [5]; a large cohort of 22,332 patients with blunt injury did not demonstrate gender-specific outcome [6]. A retrospective analysis of blunt and penetrating trauma at the University of Alabama (Birmingham, AL, USA), however, showed a significantly increased mortality rate in males younger than 50 years of age [7]. Those results are supported by Deitch and colleagues [8], who conducted a prospective cohort analysis (n = more than 4,000 trauma patients) that showed that, despite higher Injury Severity Scores (ISSs), females younger than 50 years tolerated trauma better than males did. Higher proinflammatory cytokine levels appear to be responsible for diminished outcome in male victims of trauma [9]. In burn patients, however, young females had an increased mortality rate[10,11], suggesting that different trauma mechanisms (blunt versus burn trauma) alter gender-specific outcome. In experimental studies, sex hormones have been shown to affect gender-specific immune responses. Male sex hormones are deleterious whereas female hormones are protective [2-4,12]. Hormonal status is not evaluated in most clinical studies. To define pre- versus postmenopausal by using a cutoff age of 50 years is inaccurate. Furthermore, the percentage of postmenopausal females on hormone replacement therapy is not defined. According to Hersh and colleagues [13], an estimated 21% of US women take hormone replacement medication. This should be taken into consideration when analyzing gender-specific outcomes in critically ill patients. Failure to measure hormone plasma levels significantly limits most clinical studies investigating gender differences. In summary, the prevailing hormonal milieu, and not gender, dictates immune and cardio vascular depression or maintenance following injury. Different immune responses to various disease entities have been shown in experimental and clinical studies Trauma and sepsis severity is known to affect pathophysiological mechanisms [2-4,12]. In the present study, diseases were categorized into five groups (acute coronary syndrome, CABG surgery, sepsis, trauma, and COPD exacerbation). Within those categories severity was based on APACHE (Acute Physiology and Chronic Health Evaluation) score. Specific scoring systems (that is, ISS for trauma) were not mentioned, possibly limiting the conclusiveness of the data. In clinical conditions (in contrast to experimental conditions), genetic background and comorbidities vary between critically ill patients, certainly affecting outcome. In the present study, chronic health conditions (that is, AIDS, cirrhosis, hepatic failure, lymphoma and leukemia, and tumors with metastases) were registered. Potentially relevant comorbidities (for example, diabetes) were not included. Long-term medication as well as ICU medication (that is, heparin, cyclooxgenase inhibitors, steroids, and immunesuppressants) may alter immune responses and should be considered potential confounders. In this study, however, only immunosuppressants were registered. Most studies investigating gender-specific outcome and mortality are retrospective, involving data from large registries. Despite enrolling huge numbers of patients, those studies are subject to limitations and constraints. There is no control over comprehensiveness or detail of data recorded, and information important for gender analysis (that is, hormone plasma levels, state of the estrus cycle, and pre- versus postmenopausal status) is not documented. To enhance data relevance, consideration of those potential confounders would require prospective registration of gender-specific parameters. Because clinical studies suggest that females require less ICU treatment in comparison with males [14], incorporating ICU patients may reflect a selection bias of females with reduced prognosis in comparison with the overall female population. It is also important to consider age and hormonal status when investigating outcome in critically ill patients. Specifically designed prospective studies are required to better define the exact role of gender and sex hormones in the clinical arena. Female gender itself cannot be considered a protective factor in critically ill patients. Continued research into potential sex hormone-based differences may close the gap between bench and bedside and ultimately promote therapeutic interventions to improve outcomes in males and females. In this respect, individualized estrogen treatment should be based on actual hormonal status immediately after injury.

Abbreviations

CABG: coronary artery bypass graft; COPD: chronic obstructive pulmonary disease; ICU: intensive care unit; ISS: Injury Severity Score.

Competing interests

The authors declare that they have no competing interests.
  14 in total

Review 1.  Gender dimorphism following injury: making the connection from bench to bedside.

Authors:  Jason L Sperry; Joseph P Minei
Journal:  J Leukoc Biol       Date:  2007-09-25       Impact factor: 4.962

Review 2.  Effect of gender and sex hormones on immune responses following shock.

Authors:  M K Angele; M G Schwacha; A Ayala; I H Chaudry
Journal:  Shock       Date:  2000-08       Impact factor: 3.454

Review 3.  The role of estrogen and receptor agonists in maintaining organ function after trauma-hemorrhage.

Authors:  Huang-Ping Yu; Irshad H Chaudry
Journal:  Shock       Date:  2009-03       Impact factor: 3.454

4.  Age-related gender differential in outcome after blunt or penetrating trauma.

Authors:  Richard L George; Gerald McGwin; Sam T Windham; Sherry M Melton; Jesse Metzger; Irshad H Chaudry; Loring W Rue
Journal:  Shock       Date:  2003-01       Impact factor: 3.454

5.  Mechanism of salutary effects of finasteride on post-traumatic immune/inflammatory response: upregulation of estradiol synthesis.

Authors:  Michael Frink; Ya-Ching Hsieh; Shunhua Hu; Chi-Hsun Hsieh; Hans-Christoph Pape; Mashkoor A Choudhry; Martin G Schwacha; Kirby I Bland; Irshad H Chaudry
Journal:  Ann Surg       Date:  2007-11       Impact factor: 12.969

6.  Gender-related outcomes in trauma.

Authors:  Gamal Mostafa; Toan Huynh; Ronald F Sing; William S Miles; H James Norton; Michael H Thomason
Journal:  J Trauma       Date:  2002-09

7.  A statewide population-based study of gender differences in trauma: validation of a prior single-institution study.

Authors:  Christopher J Gannon; Lena M Napolitano; Michael Pasquale; J Kathleen Tracy; Robert J McCarter
Journal:  J Am Coll Surg       Date:  2002-07       Impact factor: 6.113

8.  National use of postmenopausal hormone therapy: annual trends and response to recent evidence.

Authors:  Adam L Hersh; Marcia L Stefanick; Randall S Stafford
Journal:  JAMA       Date:  2004-01-07       Impact factor: 56.272

9.  Association of gender with outcomes in critically ill patients.

Authors:  Kamran Mahmood; Kamal Eldeirawi; Momen M Wahidi
Journal:  Crit Care       Date:  2012-05-22       Impact factor: 9.097

Review 10.  Bench-to-bedside review: latest results in hemorrhagic shock.

Authors:  Martin K Angele; Christian P Schneider; Irshad H Chaudry
Journal:  Crit Care       Date:  2008-07-10       Impact factor: 9.097

View more
  3 in total

1.  Epidemiology and outcome of severe pneumococcal pneumonia admitted to intensive care unit: a multicenter study.

Authors:  Nicolas Mongardon; Adeline Max; Adrien Bouglé; Frédéric Pène; Virginie Lemiale; Julien Charpentier; Alain Cariou; Jean-Daniel Chiche; Jean-Pierre Bedos; Jean-Paul Mira
Journal:  Crit Care       Date:  2012-08-15       Impact factor: 9.097

2.  Gender- and age-based differences in outcomes of mechanically ventilated ICU patients: a Chinese multicentre retrospective study.

Authors:  Jia-Gui Ma; Bo Zhu; Li Jiang; Qi Jiang; Xiu-Ming Xi
Journal:  BMC Anesthesiol       Date:  2022-01-10       Impact factor: 2.217

3.  Predictors of Three-month Hospital Readmissions and Mortality in Patients with Cirrhosis of Liver.

Authors:  Anurag Lavekar; Dhananjay Raje; Aarsha Sadar; Tanuja Manohar; Kavutharapu Sri Manjari; Pradeep T Satyanarayana
Journal:  Euroasian J Hepatogastroenterol       Date:  2019 Jul-Dec
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.